https://www.selleckchem.com/products/AT7867.html
uncommon cause of severe hyponatremia. The performance of the galactomannan enzyme immunoassay (GM-EIA) is impaired in patients receiving mould-active antifungal therapy. The impact of mould-active antifungal therapy on Aspergillus PCR testing needs to be determined. To determine the influence of anti-mould prophylaxis (AMP) on the performance of PCR blood testing to aid the diagnosis of proven/probable invasive aspergillosis (IA). As part of the systematic review and meta-analysis of 22 cohort studies investigating Aspergillus PCR blood
Like
Comment
Share
